• We offer tailored partnerships to support and transform drug discovery.

    Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

  • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

    As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

  • Our OrganoReady program is made for you when you need optimized assays for investigational toxicology.

    We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.
  • Get inspired by research done by our scientists, partners, and customers around the globe.

  • Learn about our mission, vision, the history of the company, and find out what we mean with MIMETAS-do.
open menu icon close menu icon
EN

£900k awarded by CRACK IT Challenges to develop TDAR-on-a-chip

Funding for development in vitro TDAR assay

Leiden, the Netherlands, February 9, 2021 The CRACK IT Challenges is a competition from the NC3Rs, aimed at funding collaborations between industry, academics, small and medium-sized enterprises. The goal of these projects is to develop innovative solutions into marketable products or services that will deliver 3Rs benefits:

  • Replacement
  • Refinement
  • Reduction

... of animals in research.

We are proud to announce that our team under the supervision of Dr. Karla Queiroz, is one of three that will be awarded Phase 1 funding for the development of a human in vitro T-cell dependent antibody response (TDAR) assay. The other winners include:

  • Jun.-Prof. Dr. Peter Loskill, Eberhard Karls University Tübingen, Germany
  • Dr Qibo Zhang, University of Liverpool, UK

The aim of this Challenge is to develop a human in vitro TDAR assay to assess the immune enhancement properties of preclinical immunomodulatory therapeutics during development, reducing the use of non-human primates for this purpose and to better predict clinical outcomes.

Why TDAR-on-a-chip?
On-target enhancement of the immune response by immunomodulatory therapeutics can cause immunotoxicity. For immune-modulating biologics this is usually assessed in the in vivo TDAR in non-human primates.

With TDAR-on-a-chip we aim to combine all the relevant cell types to assess the immune enhancement properties of preclinical immunomodulatory therapeutics in the presence of a representative spatial organization of cells. In this way, we want to model the complex nature of the immune response, which involves the interaction of several key cell types and mediators in the morphologically coordinated architecture of lymphoid organs, such as the lymph node. Furthermore, the ability of TDAR-on-a-chip to also assess immunosuppression as part of this challenge is considered advantageous.

Stay tuned for our future plans to deliver Phase 2 of the Challenge, including commercialization and dissemination. Read more about the CRACK IT Challenges.

Sign up for our Newsletter

 

Cookies

May we use cookies?
Hi there! Thanks for visiting our website. We use cookies to keep track of our website statistics to optimize the user experience. We also use cookies for marketing purposes. You can set your preferences by selecting the options below. Terms of Use & Privacy Policy
Accept all
Accept selected
Decline all